AI Research
Artificial Intelligence (AI) Software Sales Could Soar 580%: 2 AI Stocks to Buy Now (Hint: Not Palantir)

Artificial intelligence (AI) is quickly weaving its way into daily life. According to Goldman Sachs, 9.2% of U.S. companies now use AI to produce goods and services, which is twice the percentage that used the technology at the same time last year. But the market is still in its early stages.
Morgan Stanley estimates AI software revenues will increase 580% in the next three years, topping $400 billion in 2028. While Palantir is well positioned to benefit, the stock carries a steep valuation. Investors should consider more reasonably priced stocks such as MongoDB (MDB 3.40%) and Okta (OKTA 0.98%).
Read on to learn more.
Image source: Getty Images.
1. MongoDB
Databases are used to store, manage, and retrieve application data. MongoDB’s document database handles structured and unstructured data, which differentiates it from traditional relational databases designed solely for structured data. To elaborate, structured data fits neatly into rows and columns, but unstructured data (e.g., images, videos, and text) does not.
The flexibility of the document model means MongoDB is especially well-suited for content management systems, e-commerce platforms, and artificial intelligence (AI) applications. MongoDB earlier this year leaned into the AI opportunity by acquiring Voyage AI, a company that develops embedding and reranking models that improve AI application accuracy.
CEO Dev Ittycheria told analysts, “As AI redefines how applications are built and how businesses operate, MongoDB is exceptionally well positioned. Real-world applications require high-quality, context-rich, and often unstructured data to deliver trustworthy outputs.”
MongoDB’s document model is also well-suited to real-time analytics applications, which are often used to personalize customer experiences across the internet. Consultancy Gartner recently ranked MongoDB as a leader in database management systems, mentioning its support for artificial intelligence and real-time analytics.
MongoDB shares currently trade at 49 times adjusted earnings. While that is not cheap, the valuation is reasonable for a company whose adjusted earnings increased 96% in the most recent quarter. Additionally, shares trade at 7.4 times sales, a material discount to the one-year average of 9.5 times sales and the three-year average of 13.4 times sales.
2. Okta
Okta is a cybersecurity company that develops identity and access management (IAM) software. Its platform lets administrators enforce contextual access policies that define which users and devices can connect to which applications and resources. It leans on AI to score risk with each login and authenticate accounts (including AI agents) based on criteria like identity, location, and behavior.
Importantly, Okta recently introduced a new product called Identity Threat Protection, an AI-powered tool that measures session risk. To elaborate, whereas login risk is calculated only one time during the authentication phase, session risk is determined continuously by analyzing every request post-authentication.
Okta has multiple tailwinds at its back. First, cybersecurity is a nondiscretionary budget expense because businesses cannot afford to suffer a data breach. Second, identity-based attacks account for 30% of cybersecurity incidents, and the identity market is projected to grow at 12.6% annually through 2030 as AI creates new threats. Third, industry analysts recently ranked Okta as a leader in workforce identity (for employees) and customer identity.
Okta shares currently trade at 33 times adjusted earnings. That is quite reasonable for a company whose adjusted earnings increased 32% in the most recent quarter. Additionally, shares currently trades at 6.6 times sales, roughly in line with the three-year average of 6.5 times sales. The stock fell after the recent earnings report because management provided cautious guidance. Patient investors should lean into that opportunity.
Trevor Jennewine has positions in Palantir Technologies. The Motley Fool has positions in and recommends Goldman Sachs Group, MongoDB, Okta, and Palantir Technologies. The Motley Fool recommends Gartner. The Motley Fool has a disclosure policy.
AI Research
Lila Sciences raises $235 million to expand AI-driven research platform | Pharmaceutical | The Pharmaletter

Lila Sciences has secured $235 million in series A financing, co-led by Braidwell and Collective Global, at a valuation of about $1.23 billion. The Massachusetts-based company, founded by Flagship Pioneering in 2023, is building an artificial intelligence platform designed to automate and accelerate the scientific method across multiple disciplines.
The latest financing follows a $200-million seed round in March and will be used to hire staff and open new sites in Boston, San Francisco and London. These locations will house the company’s so-called AI Science Factories, facilities that integrate AI, robotics and laboratory systems to design and run experiments at scale. Lila says these factories have already conducted hundreds of thousands of studies across life science, chemistry and materials science.
Building autonomous science at scale
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Try before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
AI Research
Gachon University establishes AI·Computing Research Institute – 조선일보
AI Research
Tech war: Tencent pushes adoption of Chinese AI chips as mainland cuts reliance on Nvidia

Tencent has “fully adapted to mainstream domestic chips” and “participates in the open-source community”, Tencent Cloud president Qiu Yuepeng said at the company’s annual Global Digital Ecosystem Summit on Tuesday.
-
Business3 weeks ago
The Guardian view on Trump and the Fed: independence is no substitute for accountability | Editorial
-
Tools & Platforms1 month ago
Building Trust in Military AI Starts with Opening the Black Box – War on the Rocks
-
Ethics & Policy2 months ago
SDAIA Supports Saudi Arabia’s Leadership in Shaping Global AI Ethics, Policy, and Research – وكالة الأنباء السعودية
-
Events & Conferences4 months ago
Journey to 1000 models: Scaling Instagram’s recommendation system
-
Jobs & Careers3 months ago
Mumbai-based Perplexity Alternative Has 60k+ Users Without Funding
-
Podcasts & Talks2 months ago
Happy 4th of July! 🎆 Made with Veo 3 in Gemini
-
Education3 months ago
VEX Robotics launches AI-powered classroom robotics system
-
Education2 months ago
Macron says UK and France have duty to tackle illegal migration ‘with humanity, solidarity and firmness’ – UK politics live | Politics
-
Podcasts & Talks2 months ago
OpenAI 🤝 @teamganassi
-
Funding & Business3 months ago
Kayak and Expedia race to build AI travel agents that turn social posts into itineraries